United Therapeutics Corporation (UTHR)
USD 279.69
(-4.12%)
USD 279.69
(-4.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 984.8 Million USD | 35.4% |
| 2022 | 727.3 Million USD | 52.86% |
| 2021 | 475.8 Million USD | -7.58% |
| 2020 | 514.8 Million USD | 592.63% |
| 2019 | -104.5 Million USD | -117.74% |
| 2018 | 589.2 Million USD | 40.99% |
| 2017 | 417.9 Million USD | -41.45% |
| 2016 | 713.7 Million USD | 9.52% |
| 2015 | 651.63 Million USD | 91.62% |
| 2014 | 340.07 Million USD | 94.82% |
| 2013 | 174.56 Million USD | -42.66% |
| 2012 | 304.44 Million USD | 39.74% |
| 2011 | 217.86 Million USD | 105.7% |
| 2010 | 105.91 Million USD | 444.22% |
| 2009 | 19.46 Million USD | 145.48% |
| 2008 | -42.78 Million USD | -315.46% |
| 2007 | 19.85 Million USD | -73.15% |
| 2006 | 73.96 Million USD | 13.76% |
| 2005 | 65.01 Million USD | 320.84% |
| 2004 | 15.44 Million USD | 254.97% |
| 2003 | -9.96 Million USD | 57.85% |
| 2002 | -23.65 Million USD | 36.57% |
| 2001 | -37.28 Million USD | 50.68% |
| 2000 | -75.6 Million USD | -125.7% |
| 1999 | -33.5 Million USD | -161.72% |
| 1998 | -12.8 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 309.1 Million USD | 11.15% |
| 2024 Q2 | 278.1 Million USD | -9.3% |
| 2024 Q1 | 306.6 Million USD | 41.23% |
| 2023 Q2 | 259.2 Million USD | 7.6% |
| 2023 Q3 | 267.6 Million USD | 3.24% |
| 2023 Q4 | 217.1 Million USD | -18.87% |
| 2023 FY | 984.8 Million USD | 35.4% |
| 2023 Q1 | 240.9 Million USD | 82.36% |
| 2022 Q1 | 239.9 Million USD | 113.81% |
| 2022 FY | 727.3 Million USD | 52.86% |
| 2022 Q4 | 132.1 Million USD | -44.8% |
| 2022 Q3 | 239.3 Million USD | 106.29% |
| 2022 Q2 | 116 Million USD | -51.65% |
| 2021 Q4 | 112.2 Million USD | -31.04% |
| 2021 Q2 | 172.6 Million USD | 509.89% |
| 2021 FY | 475.8 Million USD | -7.58% |
| 2021 Q3 | 162.7 Million USD | -5.74% |
| 2021 Q1 | 28.3 Million USD | -71.36% |
| 2020 Q2 | 107.1 Million USD | -22.22% |
| 2020 Q4 | 98.8 Million USD | -42.29% |
| 2020 Q3 | 171.2 Million USD | 59.85% |
| 2020 FY | 514.8 Million USD | 592.63% |
| 2020 Q1 | 137.7 Million USD | 161.79% |
| 2019 Q1 | -494.6 Million USD | -857.43% |
| 2019 FY | -104.5 Million USD | -117.74% |
| 2019 Q2 | 205.1 Million USD | 141.47% |
| 2019 Q3 | 132.4 Million USD | -35.45% |
| 2019 Q4 | 52.6 Million USD | -60.27% |
| 2018 Q3 | 106.5 Million USD | -38.4% |
| 2018 FY | 589.2 Million USD | 40.99% |
| 2018 Q1 | 244.5 Million USD | 1186.84% |
| 2018 Q2 | 172.9 Million USD | -29.28% |
| 2018 Q4 | 65.3 Million USD | -38.69% |
| 2017 Q2 | -56 Million USD | -131.35% |
| 2017 Q4 | 19 Million USD | -93.12% |
| 2017 FY | 417.9 Million USD | -41.45% |
| 2017 Q1 | 178.6 Million USD | 61.92% |
| 2017 Q3 | 276.3 Million USD | 593.39% |
| 2016 Q4 | 110.3 Million USD | -31.83% |
| 2016 Q2 | 206.1 Million USD | -12.48% |
| 2016 Q1 | 235.5 Million USD | 125.05% |
| 2016 FY | 713.7 Million USD | 9.52% |
| 2016 Q3 | 161.8 Million USD | -21.49% |
| 2015 Q3 | 464.42 Million USD | 368.12% |
| 2015 FY | 651.63 Million USD | 91.62% |
| 2015 Q4 | 104.64 Million USD | -77.47% |
| 2015 Q2 | 99.21 Million USD | 696.18% |
| 2015 Q1 | -16.64 Million USD | -114.35% |
| 2014 Q1 | 137.52 Million USD | 553.66% |
| 2014 Q3 | -25.23 Million USD | -122.56% |
| 2014 Q4 | 115.93 Million USD | 559.39% |
| 2014 Q2 | 111.85 Million USD | -18.67% |
| 2014 FY | 340.07 Million USD | 94.82% |
| 2013 Q1 | 62.32 Million USD | -25.14% |
| 2013 FY | 174.56 Million USD | -42.66% |
| 2013 Q4 | -30.31 Million USD | -148.36% |
| 2013 Q3 | 62.68 Million USD | -21.51% |
| 2013 Q2 | 79.86 Million USD | 28.14% |
| 2012 FY | 304.44 Million USD | 39.74% |
| 2012 Q3 | 78.11 Million USD | 8.01% |
| 2012 Q1 | 70.76 Million USD | 63.84% |
| 2012 Q4 | 83.25 Million USD | 6.59% |
| 2012 Q2 | 72.31 Million USD | 2.2% |
| 2011 Q4 | 43.18 Million USD | -48.83% |
| 2011 Q2 | 73.89 Million USD | 350.83% |
| 2011 Q3 | 84.39 Million USD | 14.22% |
| 2011 FY | 217.86 Million USD | 105.7% |
| 2011 Q1 | 16.39 Million USD | 71.73% |
| 2010 Q2 | 37.7 Million USD | 99.2% |
| 2010 Q1 | 18.92 Million USD | 668.44% |
| 2010 Q3 | 39.73 Million USD | 5.38% |
| 2010 Q4 | 9.54 Million USD | -75.98% |
| 2010 FY | 105.91 Million USD | 444.22% |
| 2009 FY | 19.46 Million USD | 145.48% |
| 2009 Q4 | -3.33 Million USD | -127.9% |
| 2009 Q3 | 11.93 Million USD | 609.26% |
| 2009 Q2 | -2.34 Million USD | -117.76% |
| 2009 Q1 | 13.19 Million USD | 116.26% |
| 2008 Q2 | 14.33 Million USD | 25.68% |
| 2008 Q3 | 12.62 Million USD | -11.92% |
| 2008 Q4 | -81.14 Million USD | -742.83% |
| 2008 FY | -42.78 Million USD | -315.46% |
| 2008 Q1 | 11.4 Million USD | 474.17% |
| 2007 Q2 | 5.8 Million USD | 308.77% |
| 2007 Q4 | 1.98 Million USD | -86.62% |
| 2007 Q3 | 14.84 Million USD | 155.74% |
| 2007 Q1 | -2.78 Million USD | -105.01% |
| 2007 FY | 19.85 Million USD | -73.15% |
| 2006 Q3 | 8.47 Million USD | 10.49% |
| 2006 Q4 | 55.5 Million USD | 554.72% |
| 2006 FY | 73.96 Million USD | 13.76% |
| 2006 Q1 | 2.3 Million USD | -92.16% |
| 2006 Q2 | 7.67 Million USD | 232.6% |
| 2005 Q3 | 15.76 Million USD | 29.41% |
| 2005 FY | 65.01 Million USD | 320.84% |
| 2005 Q1 | 7.66 Million USD | 11.19% |
| 2005 Q2 | 12.18 Million USD | 59.0% |
| 2005 Q4 | 29.41 Million USD | 86.58% |
| 2004 FY | 15.44 Million USD | 254.97% |
| 2004 Q4 | 6.89 Million USD | 9.96% |
| 2004 Q3 | 6.26 Million USD | 51.35% |
| 2004 Q2 | 4.14 Million USD | 324.15% |
| 2004 Q1 | -1.84 Million USD | 42.64% |
| 2003 FY | -9.96 Million USD | 57.85% |
| 2003 Q4 | -3.22 Million USD | -140.12% |
| 2003 Q3 | -1.34 Million USD | 43.75% |
| 2003 Q2 | -2.38 Million USD | 21.16% |
| 2003 Q1 | -3.02 Million USD | -16.08% |
| 2002 Q2 | -3.18 Million USD | 43.99% |
| 2002 FY | -23.65 Million USD | 36.57% |
| 2002 Q4 | -2.6 Million USD | 78.63% |
| 2002 Q3 | -12.18 Million USD | -283.27% |
| 2002 Q1 | -5.67 Million USD | 23.55% |
| 2001 Q3 | -9.81 Million USD | 7.85% |
| 2001 Q2 | -10.64 Million USD | -13.23% |
| 2001 FY | -37.28 Million USD | 50.68% |
| 2001 Q1 | -9.4 Million USD | 70.5% |
| 2001 Q4 | -7.42 Million USD | 24.3% |
| 2000 Q3 | -7.01 Million USD | 75.65% |
| 2000 Q4 | -31.87 Million USD | -354.41% |
| 2000 FY | -75.6 Million USD | -125.7% |
| 2000 Q1 | -7.91 Million USD | 10.1% |
| 2000 Q2 | -28.81 Million USD | -264.15% |
| 1999 Q2 | -6.1 Million USD | 50.0% |
| 1999 FY | -33.5 Million USD | -161.72% |
| 1999 Q4 | -8.8 Million USD | -37.5% |
| 1999 Q1 | -12.2 Million USD | 0.0% |
| 1999 Q3 | -6.4 Million USD | -4.92% |
| 1998 FY | -12.8 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -51.92 Million USD | 1996.582% |
| Jaguar Health, Inc. | -41.3 Million USD | 2484.504% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 743.694% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 1909.562% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 323.695% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -1788.254% |
| ContextLogic Inc. | -317 Million USD | 410.662% |
| MiMedx Group, Inc. | 67.43 Million USD | -1360.283% |
| MEI Pharma, Inc. | 17.77 Million USD | -5439.431% |
| AlloVir, Inc. | -190.41 Million USD | 617.178% |
| Novavax, Inc. | -545.06 Million USD | 280.677% |
| Aptorum Group Limited | -2.82 Million USD | 34964.534% |
| Ardelyx, Inc. | -66.06 Million USD | 1590.608% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 579.747% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 2024.977% |
| Vaxcyte, Inc. | -402.26 Million USD | 344.813% |
| Precigen, Inc. | -95.9 Million USD | 1126.86% |
| Pharming Group N.V. | -10.54 Million USD | 9436.367% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 588.511% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 4112.549% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 4024.913% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 564.047% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 5410.013% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 4146.132% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 4146.132% |
| Bicycle Therapeutics plc | -180.66 Million USD | 645.1% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 481.956% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 3715.537% |
| Acelyrin, Inc. | -381.64 Million USD | 358.044% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 2737.386% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 2987.892% |
| Senti Biosciences, Inc. | -92.91 Million USD | 1159.848% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 1040.601% |
| AbCellera Biologics Inc. | -146.39 Million USD | 772.687% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 2902.504% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 650.005% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 14831.488% |
| Chimerix, Inc. | -82.09 Million USD | 1299.586% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 3453.995% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 4953.383% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 2307.908% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 2028.787% |
| Elevation Oncology, Inc. | -45.7 Million USD | 2254.735% |
| Alkermes plc | 355.75 Million USD | -176.818% |
| Fortress Biotech, Inc. | -60.63 Million USD | 1724.091% |
| Fortress Biotech, Inc. | -60.63 Million USD | 1724.091% |
| Agenus Inc. | -245.76 Million USD | 500.715% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 1307.159% |
| Dyadic International, Inc. | -6.79 Million USD | 14592.026% |
| ImmuCell Corporation | -5.77 Million USD | 17154.001% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 105313.675% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 971.805% |
| Lantern Pharma Inc. | -15.96 Million USD | 6269.833% |
| Immix Biopharma, Inc. | -15.42 Million USD | 6484.007% |
| Incyte Corporation | 597.59 Million USD | -64.793% |
| IO Biotech, Inc. | -86.08 Million USD | 1244.012% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 1789.397% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 5275.291% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 1769.643% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 698.393% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 11684.519% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 1442.659% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 363.576% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 271.914% |
| NextCure, Inc. | -62.72 Million USD | 1670.078% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 9961.807% |
| Onconetix, Inc. | -37.4 Million USD | 2732.473% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 2594.491% |
| Opthea Limited | -220.24 Million USD | 547.144% |
| PDS Biotechnology Corporation | -42.94 Million USD | 2393.315% |
| PureTech Health plc | -65.69 Million USD | 1599.003% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 1434.598% |
| Seer, Inc. | -86.27 Million USD | 1241.44% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 7851685.266% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 3131.553% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 7633.738% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 3561.268% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 1812.309% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 1681.881% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 843.285% |
| ChromaDex Corporation | -4.93 Million USD | 20043.297% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 27547.046% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 1064.828% |
| CRISPR Therapeutics AG | -153.61 Million USD | 741.104% |
| Precision BioSciences, Inc. | -61.31 Million USD | 1706.027% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 711.951% |
| Innoviva, Inc. | 179.72 Million USD | -447.957% |
| Summit Therapeutics Inc. | -614.92 Million USD | 260.149% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 1569.96% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 1597.453% |
| ESSA Pharma Inc. | -26.58 Million USD | 3804.715% |
| GlycoMimetics, Inc. | -36.89 Million USD | 2768.877% |
| GT Biopharma, Inc. | -7.59 Million USD | 13063.012% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 508.02% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -1279.079% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 2104.886% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 9999.73% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 500.985% |
| Aptose Biosciences Inc. | -51.2 Million USD | 2023.175% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 1101.852% |
| Soligenix, Inc. | -6.14 Million USD | 16137.181% |
| Century Therapeutics, Inc. | -136.67 Million USD | 820.552% |
| Kura Oncology, Inc. | -152.63 Million USD | 745.216% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 1203.813% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 9445.227% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -174056.012% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 173175.571% |
| Autolus Therapeutics plc | -208.38 Million USD | 572.591% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 1469.718% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 1491.059% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 4644.951% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 537.203% |
| GRI Bio, Inc. | -13.03 Million USD | 7653.885% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 23918.634% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 893.656% |
| IGM Biosciences, Inc. | -246.41 Million USD | 499.649% |
| INmune Bio, Inc. | -30 Million USD | 3381.792% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 990.746% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 2433.993% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 6269.785% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 6334.891% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 1749.996% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 1073.44% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 456.649% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 513.969% |
| Verastem, Inc. | -87.36 Million USD | 1227.199% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 1917.377% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 710.403% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 944.177% |
| Histogen Inc. | -10.62 Million USD | 9372.197% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 6993.097% |
| Surrozen, Inc. | -43.04 Million USD | 2387.998% |
| Organovo Holdings, Inc. | -14.67 Million USD | 6812.562% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 19459.04% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 1981.581% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 3998.191% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 3755.802% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 11884.012% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 751.819% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 2112.834% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 3413.036% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 9553.139% |
| Apollomics, Inc. | -172.6 Million USD | 670.564% |
| Amarin Corporation plc | -59.11 Million USD | 1765.99% |
| Mesoblast Limited | -87.95 Million USD | 1219.651% |
| Turnstone Biologics Corp. | -55.2 Million USD | 1884.058% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 770.105% |
| Synaptogenix, Inc. | -6.03 Million USD | 16408.675% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 6176.012% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 1362.24% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 20653.209% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 11820.745% |
| Exelixis, Inc. | 207.76 Million USD | -373.997% |
| Better Therapeutics, Inc. | -39.76 Million USD | 2576.861% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 784.136% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 286.294% |
| NLS Pharmaceutics AG | -12.17 Million USD | 8190.681% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 12734.242% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 3302.706% |
| Gritstone bio, Inc. | -138.49 Million USD | 811.098% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 1627.651% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 24720.308% |
| Avid Bioservices, Inc. | -140.75 Million USD | 799.665% |
| Insmed Incorporated | -749.56 Million USD | 231.383% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 6583.423% |
| MediWound Ltd. | -6.71 Million USD | 14763.49% |
| OmniAb, Inc. | -50.61 Million USD | 2045.515% |
| Alector, Inc. | -130.39 Million USD | 855.267% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 965.956% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 1999.435% |
| Zai Lab Limited | -334.62 Million USD | 394.304% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 403.964% |
| Aura Biosciences, Inc. | -76.4 Million USD | 1388.87% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 519.721% |
| Immunic, Inc. | -93.61 Million USD | 1152.002% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 824.688% |
| Veracyte, Inc. | -74.4 Million USD | 1423.585% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 12930.351% |
| FibroGen, Inc. | -284.23 Million USD | 446.478% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 3854.193% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 14164.774% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 5329.204% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | -137.397% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 4466.216% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -1898.742% |
| TG Therapeutics, Inc. | 12.67 Million USD | -7671.465% |
| Galecto, Inc. | -38.34 Million USD | 2667.994% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 5319.972% |
| Fortrea Holdings Inc. | -3.4 Million USD | 29064.706% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 877.613% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 5756.194% |
| XBiotech Inc. | -24.55 Million USD | 4110.262% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 1627.651% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 1671.155% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 1100.549% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 4696.07% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 1884.284% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 262.337% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 1542.825% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 1729822.134% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 534.715% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 4522.585% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 548.227% |
| NexImmune, Inc. | -32.34 Million USD | 3144.732% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 18728.321% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 7111.301% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 75.091% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 4165.893% |
| Scopus BioPharma Inc. | -11.6 Million USD | 8582.469% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 943.165% |
| Ainos, Inc. | -13.77 Million USD | 7251.494% |
| Pluri Inc. | -20.88 Million USD | 4814.669% |
| Prothena Corporation plc | -147.02 Million USD | 769.804% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 964.838% |
| Celularity Inc. | -196.29 Million USD | 601.694% |
| Rallybio Corporation | -74.56 Million USD | 1420.745% |
| Cue Biopharma, Inc. | -50.73 Million USD | 2041.143% |
| MeiraGTx Holdings plc | -84.02 Million USD | 1272.004% |
| Omeros Corporation | -117.81 Million USD | 935.901% |
| Humacyte, Inc. | -110.77 Million USD | 989.001% |
| Immunocore Holdings plc | -55.28 Million USD | 1881.251% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 5575.979% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 4394.623% |
| Blueprint Medicines Corporation | -506.98 Million USD | 294.247% |
| CalciMedica, Inc. | -34.35 Million USD | 2966.374% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 1555.19% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 796.439% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 694.008% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 447.673% |
| Pulmatrix, Inc. | -14.12 Million USD | 7074.01% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 2898.125% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 1291.704% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 304.658% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 1039.058% |
| Cytokinetics, Incorporated | -526.24 Million USD | 287.138% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 2830.625% |
| Nutriband Inc. | -5.48 Million USD | 18053.393% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 2536.418% |
| Vor Biopharma Inc. | -117.86 Million USD | 935.546% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 77.355% |
| Evogene Ltd. | -23.87 Million USD | 4224.126% |
| ProKidney Corp. | -35.46 Million USD | 2876.587% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 922.291% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 12652.595% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 253.109% |
| CorMedix Inc. | -46.33 Million USD | 2225.197% |
| BioLineRx Ltd. | -60.61 Million USD | 1724.707% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 1067.919% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 2498.091% |
| Atai Life Sciences N.V. | -40.22 Million USD | 2548.29% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 1321.076% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 1404.008% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 437.04% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 3632.788% |
| MediciNova, Inc. | -8.57 Million USD | 11589.216% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 898.851% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 11856.232% |
| GeoVax Labs, Inc. | -25.96 Million USD | 3892.541% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 511.64% |
| Biomea Fusion, Inc. | -117.25 Million USD | 939.879% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 257.165% |
| Mereo BioPharma Group plc | -29.46 Million USD | 3442.157% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 742.979% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 570.386% |
| Absci Corporation | -110.56 Million USD | 990.69% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 3366.335% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 1076.626% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 517.4% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -6892.332% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 610.36% |
| Allakos Inc. | -185.7 Million USD | 630.315% |
| Imunon, Inc. | -19.51 Million USD | 5146.381% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 1111.763% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -827.831% |
| BioAtla, Inc. | -123.46 Million USD | 897.654% |
| NLS Pharmaceutics AG | -12.17 Million USD | 8190.681% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 6225.14% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 400.918% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 2765.295% |
| XOMA Corporation | -40.83 Million USD | 2511.893% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 1066.722% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 930.964% |
| aTyr Pharma, Inc. | -50.38 Million USD | 2054.395% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 1223.188% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 748.924% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 514.244% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 2904.18% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 12270.135% |
| Akari Therapeutics, Plc | -10 Million USD | 9940.128% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 1462855.291% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -249.723% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 14875.918% |
| UroGen Pharma Ltd. | -102.24 Million USD | 1063.186% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 1022.158% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 12762.681% |
| Orgenesis Inc. | -55.36 Million USD | 1878.87% |
| Entera Bio Ltd. | -8.88 Million USD | 11178.862% |
| GH Research PLC | -35.58 Million USD | 2867.303% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 4825.528% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 1372.549% |
| Xencor, Inc. | -126.08 Million USD | 881.048% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 26251.83% |
| Replimune Group, Inc. | -215.79 Million USD | 556.361% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 4730.749% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -39150.697% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 14875.918% |
| Portage Biotech Inc. | -75.33 Million USD | 1407.158% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 11856.232% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 1118.882% |
| OncoCyte Corporation | -27.78 Million USD | 3644.869% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 7439.826% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 8954.905% |
| Purple Biotech Ltd. | -19.88 Million USD | 5053.722% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 14130.489% |
| scPharmaceuticals Inc. | -54.81 Million USD | 1896.752% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 5725.454% |
| HilleVax, Inc. | -123.56 Million USD | 896.983% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 9843.742% |
| Tharimmune, Inc. | -9.31 Million USD | 10667.551% |
| Genprex, Inc. | -30.86 Million USD | 3291.138% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 517.421% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 3372.413% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 55363.749% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 18695.113% |
| OKYO Pharma Limited | -16.82 Thousand USD | 5853134.627% |
| Savara Inc. | -54.69 Million USD | 1900.431% |
| Curis, Inc. | -47.41 Million USD | 2177.067% |
| Daré Bioscience, Inc. | -30.16 Million USD | 3365.101% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 6476.138% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 17783.606% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 3403.035% |
| BeiGene, Ltd. | -881.7 Million USD | 211.692% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 4724.777% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 325.682% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 1347.293% |
| Erasca, Inc. | -125.04 Million USD | 887.575% |
| bluebird bio, Inc. | -211.91 Million USD | 564.719% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 19794.042% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -487.432% |
| DBV Technologies S.A. | -72.72 Million USD | 1454.124% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 19794.042% |
| Moderna, Inc. | -4.71 Billion USD | 120.891% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 2552.374% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 17395.399% |
| Molecular Templates, Inc. | -8.12 Million USD | 12222.107% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 1730.788% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 984.029% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 827.584% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 2155.135% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 796.321% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 611.824% |
| MacroGenics, Inc. | -9.05 Million USD | 10972.157% |
| RenovoRx, Inc. | -10.23 Million USD | 9724.707% |
| Adicet Bio, Inc. | -142.65 Million USD | 790.322% |
| Prime Medicine, Inc. | -198.13 Million USD | 597.04% |
| Aditxt, Inc. | -32.38 Million USD | 3141.305% |
| Adagene Inc. | -18.94 Million USD | 5297.829% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 13568.782% |
| Quantum-Si incorporated | -95.96 Million USD | 1126.261% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 927.361% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 6855.492% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -644.2% |
| SciSparc Ltd. | -5.12 Million USD | 19326.865% |
| Vericel Corporation | -3.18 Million USD | 31049.089% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 819033.258% |
| Minerva Neurosciences, Inc. | -30 Million USD | 3382.081% |
| Generation Bio Co. | -126.61 Million USD | 877.809% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 1451.058% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 1294.537% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 475.677% |
| Invivyd, Inc. | -198.64 Million USD | 595.764% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 387.976% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 11437.037% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -4218.162% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 10073.668% |
| 2seventy bio, Inc. | -217.57 Million USD | 552.636% |
| ADMA Biologics, Inc. | -28.23 Million USD | 3587.376% |
| Clene Inc. | -49.5 Million USD | 2089.334% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 4518.612% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 2092.151% |
| GeoVax Labs, Inc. | -25.96 Million USD | 3892.541% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 400.183% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 3126.158% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -4234.507% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 1096.844% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 1417.388% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 712.419% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 260.114% |
| Evaxion Biotech A/S | -22.12 Million USD | 4551.073% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 1319.778% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 592.233% |
| Trevena, Inc. | -40.28 Million USD | 2544.34% |
| Surrozen, Inc. | -43.04 Million USD | 2387.998% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 1524.48% |
| Cingulate Inc. | -23.53 Million USD | 4284.416% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 14347.685% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 2570.647% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 12871.907% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 1191.675% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 1706.892% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 1755.043% |
| Clearmind Medicine Inc. | -11.95 Million USD | 8337.536% |
| Kronos Bio, Inc. | -112.67 Million USD | 974.034% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 1523.183% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 38829385.987% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 1246.516% |
| Statera Biopharma, Inc. | -174.4 Million USD | 664.652% |
| ImmunityBio, Inc. | -583.19 Million USD | 268.863% |
| Korro Bio, Inc. | -81.17 Million USD | 1313.226% |
| Kineta, Inc. | -14.09 Million USD | 7084.893% |
| BioVie Inc. | -32.12 Million USD | 3165.952% |
| Codexis, Inc. | -76.24 Million USD | 1391.71% |
| Celularity Inc. | -196.29 Million USD | 601.694% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 559.052% |
| Celcuity Inc. | -63.77 Million USD | 1644.079% |
| Virax Biolabs Group Limited | -6.73 Million USD | 14725.3% |
| Cibus, Inc. | -267.62 Million USD | 467.975% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 2542.097% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 2849.993% |
| IN8bio, Inc. | -30 Million USD | 3381.901% |
| Kodiak Sciences Inc. | -260.49 Million USD | 478.055% |
| Annexon, Inc. | -134.23 Million USD | 833.628% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 940.524% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 1708.414% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 3221.988% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 368.861% |
| Eyenovia, Inc. | -27.26 Million USD | 3712.474% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -4461.16% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 184174.766% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 1388.938% |
| Arcellx, Inc. | -70.69 Million USD | 1493.125% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 2476.391% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 835.936% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 3378.623% |
| Moolec Science SA | -51.78 Million USD | 2001.567% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 1980.43% |
| Geron Corporation | -184.12 Million USD | 634.848% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 2446.214% |
| Royalty Pharma plc | 1.13 Billion USD | 13.221% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 824.352% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 11175.369% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 4735.83% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 673.659% |
| Humacyte, Inc. | -110.77 Million USD | 989.001% |
| Structure Therapeutics Inc. | -89.62 Million USD | 1198.862% |
| 89bio, Inc. | -142.18 Million USD | 792.599% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 1528.074% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 9590.219% |
| Genelux Corporation | -28.29 Million USD | 3580.228% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 3488.268% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 656.01% |
| Notable Labs, Ltd. | -11.26 Million USD | 8842.898% |
| Liquidia Corporation | -78.5 Million USD | 1354.49% |
| Mustang Bio, Inc. | -51.6 Million USD | 2008.453% |
| Immunovant, Inc. | -259.33 Million USD | 479.739% |
| Quantum-Si incorporated | -95.96 Million USD | 1126.261% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 1451.837% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 5181.265% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 1125.94% |
| Acasti Pharma Inc. | -12.85 Million USD | 7762.024% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 4485.102% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 6269.785% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 639.933% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 22994.249% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 7997.354% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 3439.324% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 2625.905% |
| PepGen Inc. | -78.62 Million USD | 1352.512% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 3408.139% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 4524.079% |
| Solid Biosciences Inc. | -96.01 Million USD | 1125.673% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 20653.209% |
| Immuneering Corporation | -53.47 Million USD | 1941.725% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 19459.04% |
| Silo Pharma, Inc. | -3.7 Million USD | 26711.304% |
| Belite Bio, Inc | -31.63 Million USD | 3213.303% |
| XOMA Corporation | -40.83 Million USD | 2511.893% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 1911.46% |
| Bionomics Limited | -15.49 Billion USD | 106.357% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 1272.59% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 3477.577% |
| uniQure N.V. | -308.47 Million USD | 419.245% |
| Cassava Sciences, Inc. | -97.21 Million USD | 1112.992% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 13568.782% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 897.861% |
| Forte Biosciences, Inc. | -31.47 Million USD | 3228.733% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 12107.262% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 3487.918% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 184174.766% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 3854.193% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 6073.916% |
| Altimmune, Inc. | -88.44 Million USD | 1213.435% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 749.673% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 3477.577% |
| Compugen Ltd. | -18.75 Million USD | 5351.146% |
| Peak Bio, Inc. | -1259.26 USD | 78204759.88% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 2238.592% |
| Benitec Biopharma Inc. | -21.75 Million USD | 4627.608% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 390.682% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 1287.164% |
| Zura Bio Limited | -60.36 Million USD | 1731.544% |
| PolyPid Ltd. | -23.86 Million USD | 4226.545% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 6359.853% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 1287.164% |
| Instil Bio, Inc. | -156.08 Million USD | 730.93% |
| argenx SE | -295.05 Million USD | 433.771% |
| Immunome, Inc. | -106.8 Million USD | 1022.046% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 2417.504% |
| Verona Pharma plc | -54.36 Million USD | 1911.326% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 1085.618% |
| Shattuck Labs, Inc. | -87.29 Million USD | 1228.09% |
| CervoMed Inc. | -2.17 Million USD | 45443.351% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 890.046% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 7495.614% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 2361.049% |
| Moolec Science SA | -51.78 Million USD | 2001.567% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 5695308.056% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 828.848% |
| AnaptysBio, Inc. | -163.61 Million USD | 701.886% |
| Design Therapeutics, Inc. | -66.86 Million USD | 1572.884% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 1309.62% |
| NeurAxis, Inc. | -14.62 Million USD | 6832.9% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 2699.652% |
| Lumos Pharma, Inc. | -34.03 Million USD | 2993.577% |
| Achilles Therapeutics plc | -69.66 Million USD | 1513.622% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 1085.618% |
| 180 Life Sciences Corp. | -19.93 Million USD | 5040.027% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -32630.766% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 38829385.987% |
| Nutriband Inc. | -5.48 Million USD | 18053.393% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 1077.983% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 2126.046% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 1377.451% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 2999.029% |
| MoonLake Immunotherapeutics | -36 Million USD | 2835.004% |
| Palisade Bio, Inc. | -12.3 Million USD | 8106.504% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 2437.86% |
| Beam Therapeutics Inc. | -132.52 Million USD | 843.094% |
| Neurogene Inc. | -36.31 Million USD | 2811.678% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 702.637% |
| AEON Biopharma, Inc. | -52.55 Million USD | 1973.811% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 1103.393% |
| Sesen Bio, Inc. | -19.88 Million USD | 5052.726% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 1475.726% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 7969.651% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 321.783% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 982.706% |
| Athira Pharma, Inc. | -117.67 Million USD | 936.903% |
| Vaccinex, Inc. | -20.25 Million USD | 4962.97% |
| HCW Biologics Inc. | -24.99 Million USD | 4040.102% |
| XOMA Corporation | -40.83 Million USD | 2511.893% |
| Nektar Therapeutics | -276.05 Million USD | 456.739% |
| Arvinas, Inc. | -367.3 Million USD | 368.119% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 1462855.291% |
| Merus N.V. | -154.93 Million USD | 735.605% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 1110.798% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 3237.805% |
| Rezolute, Inc. | -68.45 Million USD | 1538.525% |
| Clene Inc. | -49.5 Million USD | 2089.334% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 6485.074% |
| BeyondSpring Inc. | -21.02 Million USD | 4783.725% |
| Synlogic, Inc. | -57.28 Million USD | 1819.214% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 8374.935% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 9196.619% |
| Peak Bio, Inc. | -1259.26 USD | 78204759.88% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 2735.41% |
| Krystal Biotech, Inc. | 10.93 Million USD | -8908.416% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 788.195% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 402.918% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 21420.794% |
| MannKind Corporation | -11.93 Million USD | 8349.288% |
| Ikena Oncology, Inc. | -68.16 Million USD | 1544.709% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 4786.177% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 1159.688% |
| Gossamer Bio, Inc. | -179.81 Million USD | 647.668% |
| CohBar, Inc. | -11.96 Million USD | 8332.655% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 3918.83% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 3366.335% |
| Legend Biotech Corporation | -518.25 Million USD | 290.023% |
| Mural Oncology plc | -207.44 Million USD | 574.724% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 893.458% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 5484.444% |
| Disc Medicine, Inc. | -76.42 Million USD | 1388.516% |
| Champions Oncology, Inc. | -7.27 Million USD | 13634.909% |
| REGENXBIO Inc. | -263.49 Million USD | 473.747% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 9379.121% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 2173.045% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 2692.705% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 1083.197% |
| Vaxart, Inc. | -82.46 Million USD | 1294.204% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -294959.668% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 2723.16% |
| Cellectis S.A. | -101.05 Million USD | 1074.48% |
| Longeveron Inc. | -21.41 Million USD | 4699.075% |
| Repare Therapeutics Inc. | -93.79 Million USD | 1149.938% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 283.739% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 1483.749% |
| Revolution Medicines, Inc. | -436.36 Million USD | 325.682% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 15087.064% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 3294.913% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 1520.391% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 1621.35% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 10137.713% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 72.793% |
| Denali Therapeutics Inc. | -145.22 Million USD | 778.125% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 819033.258% |
| Veru Inc. | -93.15 Million USD | 1157.189% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 3743.494% |
| Cingulate Inc. | -23.53 Million USD | 4284.416% |
| Passage Bio, Inc. | -102.06 Million USD | 1064.904% |
| Context Therapeutics Inc. | -23.96 Million USD | 4209.461% |
| Exicure, Inc. | -16.91 Million USD | 5922.396% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 621.287% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 2707.775% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 15233.716% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 633.252% |
| Nuvalent, Inc. | -126.21 Million USD | 880.231% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 9465.084% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 1233.531% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 3324.201% |
| OmniAb, Inc. | -50.61 Million USD | 2045.515% |
| Anew Medical, Inc. | 1.34 Million USD | -73058.139% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 6237.738% |
| Lipocine Inc. | -16.35 Million USD | 6122.475% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 1583.267% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 1646.604% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 2433.993% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 2153.078% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 5065.962% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 281.869% |
| Ocugen, Inc. | -63.07 Million USD | 1661.242% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 1128.705% |
| Q32 Bio Inc. | -112.96 Million USD | 971.805% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 5828.246% |
| Alumis Inc. Common Stock | -154.99 Million USD | 735.384% |
| Equillium, Inc. | -13.33 Million USD | 7485.077% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 1731.382% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 12428.746% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 5324.063% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 1766.836% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 959.885% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 5458.594% |
| Dominari Holdings Inc. | -22.88 Million USD | 4403.82% |
| Edesa Biotech, Inc. | -8.37 Million USD | 11859.627% |
| vTv Therapeutics Inc. | -20.25 Million USD | 4963.21% |
| Bio-Techne Corporation | 168.1 Million USD | -485.824% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 379.703% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -664.282% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 908.326% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 2695.746% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 974.274% |
| Nkarta, Inc. | -117.5 Million USD | 938.121% |
| BioCardia, Inc. | -11.57 Million USD | 8610.933% |
| Iterum Therapeutics plc | -38.37 Million USD | 2666.522% |